Kymera Therapeutics, Inc.
KYMR
Rangering i aksjer
#2153
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to... Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
Aksjekurs
$112.78
Markedsverdi
$9.28B
Endring (1 dag)
0.13%
Endring (1 år)
102.11%
Land
US
Handel Kymera Therapeutics, Inc. (KYMR)
Kategori
Healthcare
Aksjeprishistorikk for Kymera Therapeutics, Inc. (KYMR)
Høyeste sluttskurs: $109.31 den 2026-10-01
Laveste sluttskurs: $31.67 den 2020-08-01
Laveste sluttskurs: $31.67 den 2020-08-01
Aksjeprishistorikk for Kymera Therapeutics, Inc. fra 2020 til 2026
Årlig aksjeprisytelse
| År | Ytelse |
|---|---|
| 2026 (TTM) | 12.16% |
| 2025 | 87.59% |
| 2024 | 77.01% |
| 2023 | -11.39% |
| 2022 | -52.05% |
| 2021 | -12.80% |
| 2020 | 0.00% |
Aksjepris for lignende selskaper eller konkurrenter
| Selskap | Aksjepris | Endring 1år% | Land |
|---|---|---|---|
| $536.98 | 25.92% |
US
|
|
| $224.77 | 737.11% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $876.75 | 7.69% |
NL
|
